Michael Frohman, MD, PhD

My laboratory cloned the mammalian family of lipid-signaling Phospholipase D genes and has worked on them for the past 27 years while being continuously funded from the NIH and publishing more than 100 peer-reviewed articles and reviews on PLD and other lipid signaling topics with additional ones in submission. PLD superfamily members are involved in many physiological and pathophysiological settings including immune mitochondrial biology and cardiovascular disease. Among other approaches, we have been generating and publishing findings with mice lacking each of the PLD isoforms and have uncovered a number of fascinating stories with human health relevance. Recent work has included exploring the potential of using a Phospholipase D small molecule inhibitor as a therapeutic in stroke and cancer progression; additional manuscripts on the cancer-focused topic are currently in revision.

Distinguished Professor and Chair of Pharmacological Sciences
michael.frohman@stonybrook.edu
https://www.pharm.stonybrook.edu/faculty/f/frohman